Renovion
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
900 Mlk Jr Blvd Ste A, Chapel Hill, Nort...Phone Number
(919) 314-8340Website
www.renovion.comRevenue
$10.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Renovion
Renovion is a clinical-stage company dedicated to developing nebulizer therapies, specifically ARINA1, to improve lung function and alleviate mucus accumulation for patients with conditions such as lung transplants, non-cystic fibrosis bronchiectasis, and chronic bronchitis. Their focus is on restoring lung health and enhancing the clearance of mucus from airways, thereby improving patients’ quality of life. The company is actively involved in clinical trials and aims to make significant advancements in lung health treatments. Renovion’s innovations are targeted primarily at individuals suffering from severe pulmonary conditions that hinder effective breathing.Explore more
Renovion Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Renovion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Renovion has recently received funding, and reach out quickly before it becomes old news!
Check out if Renovion is spiking on competitors!
Earning: See what the market has to say on Renovion recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Renovion
Funding: Get notified immidiatlly once Renovion has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Renovion launches new products
Click to see if Renovion had a recent Job posting/layoffs
Renovion, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Renovion
Find 3 more new buyers
Compare Similar Companies to Renovion
Compare insights from companies similar to Renovion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.2M
11-50
Private
-
-
Company Profile Activity
Activity Insights
Renovion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Renovion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Renovion.
Renovion financials insights
Gather financial insights about Renovion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Unspecified
$1.8M
2020
Unspecified
$5M
Series A
$8.1M
Renovion Tech Stack
A closer look at the technologies used by Renovion
Most Recent Scoops
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Funding
Funding
Funding
Renovion News & Media
Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis
CHAPEL HILL, N.C.--(BUSINESS WIRE)-- #biotechnology--Renovion Inc., a biopharmaceutical company focused on restoring lung health in patients with bronchiectasis and other lung diseases, announced that adult patient enrollment is complete in the Phase 2 CLIMB study of ARINA-1 in non-CF bronchiectasis patients. CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participants with bronchiectasis. Efficacy enFirst Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
CHAPEL HILL, N.C.--(BUSINESS WIRE)-- #COPD--Renovion, Inc. today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating ARINA-1, an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant. "ARINA-1 has the potential to be implemented early in pulmonary function decline in patients who are experiencing early signs of BOS. It has a strong safety profile andRenovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients
CHAPEL HILL, N.C.--(BUSINESS WIRE)-- #COPD--Renovion, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARINA-1 for the prevention of bronchiolitis obliterans syndrome (BOS) progression in adults with a bilateral lung transplant. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. It allows for rolling submission of regulatoryRenovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis
CHAPEL HILL, N.C. & MIAMI--(BUSINESS WIRE)-- #COPD--Renovion and COPD Foundation Joint Release – Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) (NCT05495243). "ARINA-1 has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties," said Carolyn Durham, Ph.D., Chief Scientific Officer of Renovion. "M
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Renovion
Sign Up For FreeTo access detailed company insights
Renovion is a clinical-stage company dedicated to developing nebulizer therapies, specifically ARINA1, to improve lung function and alleviate mucus accumulation for patients with conditions such as lung transplants, non-cystic fibrosis bronchiectasis, and chronic bronchitis. Their focus is on restoring lung health and enhancing the clearance of muc... Read More
